Skip to content

Darunavir once-daily approved in Europe for treatment-experienced

Once-daily darunavir approved for some treatment-experienced patients in US

Darunavir working well for highly treatment-experienced patients in Switzerland

Darunavir/ritonavir as effective in women as men

Protease inhibitor to raltegravir switch maintains viral suppression, but NRTI resistance lowers efficacy

Once-daily Kaletra approved for some treatment-experienced adults

Protease inhibitor monotherapy in clinical practice: valid option for undetectable patients

Resistance tests useful for patients with very low viral loads

Darunavir/ritonavir, etravirine and raltegravir combination has 'remarkable' success in children with resistant virus